These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25634230)

  • 1. Single-dose rituximab for recurrent glomerulonephritis post-renal transplant.
    Spinner ML; Bowman LJ; Horwedel TA; Delos Santos RB; Klein CL; Brennan DC
    Am J Nephrol; 2015; 41(1):37-47. PubMed ID: 25634230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent and de novo glomerulonephritis following renal transplantation: higher rates of rejection and lower graft survival.
    Mirioglu S; Caliskan Y; Goksoy Y; Gulcicek S; Ozluk Y; Sarihan I; Seyahi N; Kilicaslan I; Turkmen A; Sever MS
    Int Urol Nephrol; 2017 Dec; 49(12):2265-2272. PubMed ID: 29039058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of recurrent glomerulonephritis on renal graft survival.
    Toledo K; Pérez-Sáez MJ; Navarro MD; Ortega R; Redondo MD; Agüera ML; Rodríguez-Benot A; Aljama P
    Transplant Proc; 2011; 43(6):2182-6. PubMed ID: 21839228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation.
    Sprangers B; Lefkowitz GI; Cohen SD; Stokes MB; Valeri A; Appel GB; Kunis CL
    Clin J Am Soc Nephrol; 2010 May; 5(5):790-7. PubMed ID: 20185599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association of acute rejection vs recurrent glomerular disease with graft outcomes after kidney transplantation.
    Singh T; Astor BC; Zhong W; Mandelbrot DA; Maursetter L; Panzer SE
    Clin Transplant; 2019 Dec; 33(12):e13738. PubMed ID: 31630440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination treatment of low dose Anti-Thymocyte Globulin (ATG), Rituximab and high dose Sirolimus as induction agents in immune-conditioned recipients.
    Ravichandran P; Natrajan T; Jaganathan R
    Int Immunopharmacol; 2006 Dec; 6(13-14):1973-6. PubMed ID: 17161350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature.
    Kong WY; Swaminathan R; Irish A
    Int Urol Nephrol; 2013 Jun; 45(3):795-802. PubMed ID: 22798030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Graft loss from recurrent glomerulonephritis is not increased with a rapid steroid discontinuation protocol.
    Ibrahim H; Rogers T; Casingal V; Sturdevant M; Tan M; Humar A; Gillingham K; Matas A
    Transplantation; 2006 Jan; 81(2):214-9. PubMed ID: 16436965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors associated with poor graft outcomes in renal recipients with post-transplant glomerulonephritis.
    Requião-Moura LR; Moscoso-Solorzano GT; Franco MF; Ozaki KS; Pacheco-Silva A; Kirsztajn GM; Câmara NO
    Clin Transplant; 2007; 21(3):363-70. PubMed ID: 17488386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of recurrent glomerulonephritis and acute rejection episodes in zero human leukocyte antigen-mismatched kidney transplantation.
    Jeon HJ; Kim YS; Lee SM; Ahn C; Ha J; Kim SJ; Kim DK
    Transplant Proc; 2012 Apr; 44(3):600-6. PubMed ID: 22483448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities.
    Cho HH; Jin SP; Chung JH
    J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):186-91. PubMed ID: 23356542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab.
    Guiard E; Karras A; Plaisier E; Duong Van Huyen JP; Fakhouri F; Rougier JP; Noel LH; Callard P; Delahousse M; Ronco P
    Clin J Am Soc Nephrol; 2011 Jul; 6(7):1609-16. PubMed ID: 21700823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcome in patients with chronic antibody-mediated rejection treated with and without rituximab and intravenous immunoglobulin combination therapy.
    Chung BH; Kim Y; Jeong HS; Hong YA; Choi BS; Park CW; Choi YJ; Kim YS; Yang CW
    Transpl Immunol; 2014 Sep; 31(3):140-4. PubMed ID: 25179826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Beneficial Role Of Anti-Phospholipase A2 Receptor Auto-Antibodies And Rituximab In The Management Of Recurrent Primary Membranous Nephropathy After Kidney Transplantation.
    Anjum N; Nabi Z
    J Ayub Med Coll Abbottabad; 2021; 33(2):315-318. PubMed ID: 34137554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of rituximab therapy for treatment of acute humoral rejection.
    Kaposztas Z; Podder H; Mauiyyedi S; Illoh O; Kerman R; Reyes M; Pollard V; Kahan BD
    Clin Transplant; 2009; 23(1):63-73. PubMed ID: 19200217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of post-transplant glomerulonephritis].
    Sandrini S; Valerio F
    G Ital Nefrol; 2008; 25 Suppl 44():99-106. PubMed ID: 19048593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histopathologic features of transplant glomerulopathy associated with response to therapy with intravenous immune globulin and rituximab.
    Kahwaji J; Najjar R; Kancherla D; Villicana R; Peng A; Jordan S; Vo A; Haas M
    Clin Transplant; 2014 May; 28(5):546-53. PubMed ID: 24579925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab induction therapy in highly sensitized kidney transplant recipients.
    Yin H; Wan H; Hu XP; Li XB; Wang W; Liu H; Ren L; Zhang XD
    Chin Med J (Engl); 2011 Jul; 124(13):1928-32. PubMed ID: 22088448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
    Smith RM; Jones RB; Guerry MJ; Laurino S; Catapano F; Chaudhry A; Smith KG; Jayne DR
    Arthritis Rheum; 2012 Nov; 64(11):3760-9. PubMed ID: 22729997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab for remission induction in recurrent ANCA-associated glomerulonephritis postkidney transplant.
    Murakami C; Manoharan P; Carter-Monroe N; Geetha D
    Transpl Int; 2013 Dec; 26(12):1225-31. PubMed ID: 24118474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.